An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma

Xu, Jing; Ding, Tao; He, Qi; Yu, Xinmiao; Wei, Wu; Jia, Wei Hua; Yun, Jing Ping; Zhang, Ying; Shi, Ming; Shao, Chun Kui; Pan, Wei; Xiao, Yin; Min, Jun Ki; Zhuang, Shi‐Mei; Zheng, Limin

doi:10.1016/j.jhep.2012.03.027

Cited by 42 publications

(58 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The follow-up procedures from our previous study were adopted [17]. Data were censored at the last follow-up for patients without recurrence or death.…”

Section: Methodsmentioning

confidence: 99%

“…The paraffin-embedded sections were prepared as described previously [17]. In brief, formalin-fixed tissues were paraffin-embedded, cut into 4-μm sections using a microtome, and dried.…”

Section: Methodsmentioning

confidence: 99%

“…The TMA was constructed as described previously [17]. Briefly, each representative area was pre-marked in the paraffin-embedded blocks on the basis of the hematoxylin and eosin (H&E) staining, excluding necrotic and hemorrhagic areas.…”

Section: Methodsmentioning

confidence: 99%

“…IHC was performed as described in our previous study [17]. In short, the sections were sequentially deparaffinization and re-hydrated with xylene and a decreasing ethanol series.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma

Sun

et al. 2016

PLoS ONE

Self Cite

View full text Add to dashboard Cite

An emerging hallmark of cancer is reprogrammed cellular metabolism, and several cancers involve increased glucose intake and glutamine addiction. Hepatocellular carcinoma (HCC) is one of the most fatal cancers, and its molecular basis needs to be delineated to identify biomarkers for its potential treatment without resection. Therefore, this study aimed to determine the metabolism status of HCC by evaluating the expression of the glucose transporter GLUT1 and glutamine transporter ASCT2. We enrolled 192 patients with surgically resected HCC in this study. Their tissue samples were subjected to immunohistochemistry to detect GLUT1 and ASCT2 expression. The prognostic value of GLUT1 and ASCT2 expression and their combined metabolic index was determined by Kaplan–Meier analysis and the Cox proportional hazards model. We found that GLUT1 and ASCT2 expression was significantly upregulated in tumor tissues as compared to adjacent non-tumor tissues and was positively associated with tumor size. Survival analysis revealed that patients with high GLUT1 or ASCT2 expression had poor overall survival (OS) and recurrence-free survival (RFS). In HCC patients, ASCT2 expression was an independent negative prognostic factor for OS (hazard ratio [HR], 1.760; 95% confidence interval [CI] = 1.124−2.755; p = 0.013) and the metabolic index was an independent negative prognostic factor for OS (HR = 1.672, 95% CI = 1.275−2.193, p < 0.001) and RFS (HR = 1.362, 95% CI = 1.066−1.740, p = 0.013). In conclusion, the tumor metabolism status determined by expression of GLUT1 and ASCT2 and their metabolic index is a promising prognostic predictor for HCC patients.

show abstract

“…The follow-up procedures from our previous study were adopted [17]. Data were censored at the last follow-up for patients without recurrence or death.…”

Section: Methodsmentioning

confidence: 99%

“…The paraffin-embedded sections were prepared as described previously [17]. In brief, formalin-fixed tissues were paraffin-embedded, cut into 4-μm sections using a microtome, and dried.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…IHC was performed as described in our previous study [17]. In short, the sections were sequentially deparaffinization and re-hydrated with xylene and a decreasing ethanol series.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma

Sun

et al. 2016

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…The SVM data processing methods were conducted as previously described. (22,31,32) The programs were coded using R software; scripts are available on request.…”

Section: Immunohistochemistry (Ihc) and Image Analysismentioning

confidence: 99%

Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit

Jiang

Xie

Han

et al. 2018

Clinical Cancer Research

126

109

View full text Add to dashboard Cite

TNM staging system of gastric cancer (GC) is not adequate for definition of prognosis and cannot predict the candidates who are likely to benefit from chemotherapy. In this research, we constructed a GC-SVM classifier integrating 3 clinicopathologic features and 8 IHC features in the training cohort of 251 patients. And further validation of the GC-SVM classifier was performed in two validation cohort of 535 patients.Multivariate analysis revealed that the GC-SVM classifier was an independent prognostic factor. Furthermore, the classifier had higher predictive accuracy for OS and DFS than TNM stage and can added prognostic value to the TNM staging system. Moreover, the GC-SVM classifier might be able to predict which patients will benefit from adjuvant chemotherapy. Thus, the classifier could facilitate patient counseling and individualized management. Conclusion:The newly developed GC-SVM classifier was a powerful predictor of OS and DFS. Moreover, the GC-SVM classifier could predict which patients with stage II and III GC benefit from adjuvant chemotherapy.

show abstract

Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma

et al. 2019

View full text Add to dashboard Cite

Background Treatments based on the inhibition of pivotal signals of cancer stem cells (CSCs) are on a promising track. Recent studies have shown that targeting CSCs with broader immune‐based therapeutic methods, for example, the anti‐CD47 treatment, may serve as a more potent strategy for eliminating these intractable cells. We aimed to explore the prognostic effects of CD47/CD133 and the potential therapeutic significance of CD47 in esophageal squamous cell carcinoma (ESCC). Methods Immunohistochemistry was employed to identify the characteristics of CD47 and CD133 in 26 pairs of tumor tissues and adjacent non‐tumor tissues and 136 ESCC tissues. Kaplan‐Meier analysis and Cox proportional hazards models were built for estimating the prognostic values of CD47 and CD133 expression and their combined stemness index. Sphere formation assays were undertaken to explore the effects of CD47 inhibition on primary human ESCC CSCs. Results Results conclude that CD47 and CD133 expression is increased in tumor tissues as compared to adjacent non‐tumor tissues. A positive correlation between CD47/CD133 expression and differentiation was found in 136 ESCC patients. Survival analysis indicated that patients with high CD47 or CD133 expression exhibited poor overall survival and progression‐free survival (PFS). The combination of high CD47 and CD133 expression was a reliable independent prognostic factor for both OS (HR = 1.940, 95% CI = 1.399‐2.690, P < 0.0001) and progression‐free survival (HR = 1.883, 95% CI = 1.384‐2.562, P < 0.0001). Notably, CD47+ CD133+ ESCC cells were observed to possess the characteristics of CSCs, and anti‐CD47 treatment veritably eliminated the CSCs pool. Conclusions The stemness index determined by the expression of CD47 and CD133 is a promising prognostic predictor, and CD47 is a potential therapeutic target for CSCs in ESCC patients.

show abstract

An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma

Cited by 42 publications

References 37 publications

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma

GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma

Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit

Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma

Contact Info

Product

Resources

About